seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
HKMPYHKMPYOTC
Loading
Latest News
Loading news...
seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
prnewswire.com
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Ready-to-use sepsis therapy marks new advancement in time-critical treatment LONDON , Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name TYZAVAN™ (vancomycin injection, USP).1 TYZAVAN™ is offered in pre-filled ready-to-use bags that will help hospitals, pharmacists, doctors, and nurses treat patients faster, more easily, and with reduced risk. This is another example of how Hikma is using its capabilities as a leading generic pharmaceutical company to serve the growing needs of U.S. medical professionals and their patients.
proactiveinvestors.co.uk
Hikma Pharmaceuticals: Due a dose of confidence
After a rough six months in which its shares have shed a quarter of their value, Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) looks ready for a rebound. Panmure Liberum thinks the sell-off is overdone, arguing that short-term wobbles in its injectables division have been mistaken for deeper weakness.
seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPY) Shareholder/Analyst Call Transcript
Hikma Pharmaceuticals PLC (OTCPK:HKMPY) Shareholder/Analyst Call November 6, 2025 4:30 AM EST Company Participants Riad Mishlawi - Interim Head of Injectables Business, CEO & Director Khalid Nabilsi - Chief Financial Officer Conference Call Participants Zain Ebrahim - JPMorgan Chase & Co, Research Division Charlie Haywood - BofA Securities, Research Division Christian Glennie - Stifel, Nicolaus & Company, Incorporated, Research Division Victor Floch - BNP Paribas, Research Division Beatrice Fairbairn - Joh. Berenberg, Gossler & Co. KG, Research Division Kane Slutzkin - Deutsche Bank AG, Research Division James Vane-Tempest - Jefferies LLC, Research Division Sebastien Jantet - Panmure Liberum Limited, Research Division Miles Dixon - Peel Hunt LLP, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to Hikma November 2025 Trading Update.
defenseworld.net
Hikma Pharmaceuticals (OTCMKTS:HKMPY) Shares Up 0.9% – Should You Buy?
Hikma Pharmaceuticals PLC (OTCMKTS:HKMPY - Get Free Report) shot up 0.9% on Friday. The stock traded as high as $48.96 and last traded at $48.96. 332 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 1,871 shares. The stock had previously closed at $48.50. Hikma Pharmaceuticals Stock
seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Pre Recorded Earnings Call Transcript
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q2 2025 Pre Recorded Earnings Conference Call August 7, 2025 2:00 AM ET Company Participants Khalid Waleed Hosny Al Nabilsi - Chief Financial Officer Riad Ali Mishlawi - CEO & Director Riad Ali Mishlawi Thank you, everyone, for joining our 2025 half year results presentation. I'm Riad Mishlawi, CEO of Hikma, and I am joined here by Khalid Nabilsi, our CFO.
seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Q&A Earnings Call Transcript
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q2 2025 Q&A Earnings Call August 7, 2025 4:00 AM ET Company Participants Khalid Waleed Hosny Al Nabilsi - Chief Financial Officer Riad Ali Mishlawi - CEO & Director Conference Call Participants Beatrice Rose Fairbairn - Joh. Berenberg, Gossler & Co. KG, Research Division James Daniel Gordon - JPMorgan Chase & Co, Research Division Kane Slutzkin - Deutsche Bank AG, Research Division Sebastien Guillaume-Bernard Jantet - Panmure Liberum Limited, Research Division Sidhartha Modi - Barclays Bank PLC, Research Division Victor Floch - BNP Paribas Exane, Research Division Xue Chen - Barclays Bank PLC, Research Division Operator Welcome to Hikma's 2025 Interim Results meeting with our CEO, Riad Mishlawi; and CFO of Khalid Nabilsi.
reuters.com
Hikma Pharmaceuticals tumbles after injectables margin outlook cut
Shares of Hikma Pharmaceuticals fell as much as 10% on Thursday after a strong euro prompted the group to lower margin outlook for its injectables unit, despite beating expectations for overall interim profit and maintaining annual group outlook.
prnewswire.com
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON , July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name TYZAVAN™ (Vancomycin Injection, USP), by the US Food and Drug Administration (FDA). TYZAVAN™ is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved: (i) septicemia; (ii) infective endocarditis; (iii) skin and skin structure infections; (iv) bone infections; and (v) lower respiratory tract infections.
prnewswire.com
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio , June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide.
prnewswire.com
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera's third FDA approved product.
prnewswire.com
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera's third FDA approved product.
prnewswire.com
Hikma acquires Novugen's FDA-approved ANDA for trametinib
LONDON , April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug Application (ANDA) for trametinib tablets from Novugen. Hikma also announces it has entered into a commercial agreement with Novugen where Hikma will be responsible for all US sales and marketing of this product, which Novugen will manufacture and supply to Hikma.
seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPF) Q4 2024 Earnings Call Pre-Recorded (Transcript)
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q4 2024 Results Conference Call February 26, 2025 2:00 AM ET Company Participants Riad Mishlawi - Chief Executive Officer Khalid Nabilsi - Chief Financial Officer Riad Mishlawi Thank you for joining our 2024 full year results presentation. I am Riad Mishlawi, CEO of Hikma, and I am joined here with Khalid Nabilsi, our CFO.
prnewswire.com
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg
LONDON , Jan. 14, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the sale of KLOXXADO® naloxone HCl nasal spray 8 mg in the U.S. and Canada. KLOXXADO® was approved by the US Food and Drug Administration (FDA) in April 2021 for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.
prnewswire.com
Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day
LONDON, Aug. 20, 2024 /PRNewswire/ -- Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia.
prnewswire.com
KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months
LONDON , Aug. 15, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the shelf-life extension of KLOXXADO® (naloxone HCl) nasal spray 8mg from 24 to 36 months. KLOXXADO® packaging has been updated with 36-month dating, starting with product manufactured in March 2024.
seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Pre-Recorded Presentation Transcript
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q2 2024 Pre-Recorded Presentation August 8, 2024 2:30 AM ET Company Participants Riad Mishlawi - CEO & Director Khalid Nabilsi - CFO Riad Mishlawi Thank you for joining our 2024 half year results presentation. I'm Riad Mishlawi, CEO of Hikma, and I'm joined here with Khalid Nabilsi, our CFO.
proactiveinvestors.co.uk
Hikma Pharmaceuticals rallies following bullish first-half earnings
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares bounced 7.6% higher on Thursday following publication of its half-year financial report. “We had an excellent first half of the year.